Related references
Note: Only part of the references are listed.Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial
Fabio Conforti et al.
EUROPEAN JOURNAL OF CANCER (2020)
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
C. Le Pechoux et al.
ANNALS OF ONCOLOGY (2020)
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio
Ashwin Shinde et al.
LUNG CANCER (2019)
Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma
Keeratikarn Boonyawan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong et al.
LANCET ONCOLOGY (2018)
Effect of postoperative radiotherapy on outcome in resectable stage IIIA-N2 non-small-cell lung cancer: an updated meta-analysis
Nazmus Sakib et al.
NUCLEAR MEDICINE COMMUNICATIONS (2018)
The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume
Wen Feng et al.
BMC CANCER (2015)
Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base
Cliff G. Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non-Small-Cell Lung Cancer Using the National Cancer Database
Christopher D. Corso et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer
Suchit H. Patel et al.
LUNG CANCER (2014)
Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis
Charlotte Billiet et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Postoperative Radiotherapy for Resected Pathological Stage IIIA-N2 Non-Small Cell Lung Cancer: A Retrospective Study of 221 Cases from a Single Institution
Honghai Dai et al.
ONCOLOGIST (2011)
POSTOPERATIVE RADIOTHERAPY IN THE MANAGEMENT OF RESECTED NON-SMALL-CELL LUNG CARCINOMA: 10 YEARS' EXPERIENCE IN A SINGLE INSTITUTE
Omur Karakoyun-Celik et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Why we should be wary of single-center trials
Rinaldo Bellomo et al.
CRITICAL CARE MEDICINE (2009)
Impact of postoperative radiation therapy on survival in patients with complete resection and Stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial
Jean-Yves Douillard et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small cell lung cancer: cancer and leukemia group B 9734
Michael C. Perry et al.
CLINICAL LUNG CANCER (2007)
Postoperative radiotherapy for stage II or III non-small-cell lung cancer using th surveillance, epidemiology, and end results database
Brian E. Lally et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer:: 5-year follow-up of a phase II study
DC Betticher et al.
BRITISH JOURNAL OF CANCER (2006)
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
Jean-Yves Douillard et al.
LANCET ONCOLOGY (2006)
Share Paper
